FI4497438T3 - Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja - Google Patents
Trisyklisiä parp1:n estäjiä ja niiden käyttötapojaInfo
- Publication number
- FI4497438T3 FI4497438T3 FIEP24217893.7T FI24217893T FI4497438T3 FI 4497438 T3 FI4497438 T3 FI 4497438T3 FI 24217893 T FI24217893 T FI 24217893T FI 4497438 T3 FI4497438 T3 FI 4497438T3
- Authority
- FI
- Finland
- Prior art keywords
- tricyclic
- parp1 inhibitors
- pharmaceutically acceptable
- parp1
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (4)
1. Yhdiste, jolla on kaava H F O N N © DO: 9 > taisenfarmaseuttisesti hyväksyttävä suola tai tautomeeri.
2. Patenttivaatimuksen 1 mukainen yhdiste, joka on H F O N N 9 JA, O -
3. Lääkekoostumus, joka käsittää farmaseuttisesti hyväksyttävää apuainetta ja jonkin — patenttivaatimuksen 1 mukaista yhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa tai tautomeeriä.
4. Patenttivaatimuksen 3 mukainen — lääkekoostumus, joka = käsittää — patenttivaatimuksen 2 mukaista yhdistettä.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336078P | 2022-04-28 | 2022-04-28 | |
| US202263381482P | 2022-10-28 | 2022-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4497438T3 true FI4497438T3 (fi) | 2025-10-20 |
Family
ID=88420972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP23797297.1T FI4355749T3 (fi) | 2022-04-28 | 2023-04-27 | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| FIEP24217893.7T FI4497438T3 (fi) | 2022-04-28 | 2023-04-27 | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP23797297.1T FI4355749T3 (fi) | 2022-04-28 | 2023-04-27 | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11795173B1 (fi) |
| EP (3) | EP4497438B1 (fi) |
| JP (2) | JP7728989B2 (fi) |
| CN (1) | CN119173516A (fi) |
| AU (2) | AU2023259236B2 (fi) |
| CA (1) | CA3250945A1 (fi) |
| CL (1) | CL2024003262A1 (fi) |
| CO (1) | CO2024014603A2 (fi) |
| CR (1) | CR20240461A (fi) |
| DK (2) | DK4497438T3 (fi) |
| DO (1) | DOP2024000218A (fi) |
| ES (1) | ES3038967T3 (fi) |
| FI (2) | FI4355749T3 (fi) |
| HR (2) | HRP20250969T1 (fi) |
| HU (1) | HUE072274T2 (fi) |
| IL (1) | IL316278A (fi) |
| LT (2) | LT4497438T (fi) |
| MX (2) | MX2025008920A (fi) |
| PL (1) | PL4355749T3 (fi) |
| PT (2) | PT4355749T (fi) |
| SI (1) | SI4355749T1 (fi) |
| TW (1) | TWI891000B (fi) |
| WO (1) | WO2023212219A1 (fi) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL320829A (en) | 2022-01-21 | 2025-07-01 | Xinthera Inc | PARP1 inhibitors and their uses |
| JP2025510646A (ja) | 2022-03-14 | 2025-04-15 | スラップ ファーマシューティカルズ エルエルシー | 多環式化合物 |
| PT4355749T (pt) | 2022-04-28 | 2025-08-13 | Xinthera Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| IL320626A (en) * | 2022-11-10 | 2025-07-01 | Haihe Biopharma Co Ltd | Fused tricyclic parp1 inhibitor, method of preparation thereof, and use thereof |
| TW202525808A (zh) * | 2023-09-13 | 2025-07-01 | 大陸商上海瑛派藥業有限公司 | 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物 |
| WO2025080589A1 (en) * | 2023-10-09 | 2025-04-17 | Incyte Corporation | Processes for preparing kras inhibitors |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| EP2215075B1 (en) | 2007-10-26 | 2013-12-11 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as parp inhibitors |
| CN101925383A (zh) | 2007-12-11 | 2010-12-22 | 赛特帕斯凡德株式会社 | 甲酰胺化合物及其作为趋化因子受体激动剂的应用 |
| BRPI1007358A2 (pt) | 2009-01-23 | 2018-03-06 | Takeda Pharmaceutical Company Limited | inibidores de poli (adp-ribose) polimerase (parp) |
| US8541417B2 (en) | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| BR112012005970A2 (pt) | 2009-09-16 | 2015-09-08 | Cylene Pharmaceuticals Inc | moduladores tricíclicos de proteína quinase |
| PL2912032T3 (pl) | 2012-10-26 | 2020-11-16 | Nerviano Medical Sciences S.R.L. | Pochodne 4-karboksyamido-izoindolinonu jako selektywne inhibitory parp-1 |
| CN104370898A (zh) | 2013-08-14 | 2015-02-25 | 黄传满 | 咪唑并[1,2-a]吡啶类化合物及其制备方法和用途 |
| AU2015226881A1 (en) | 2014-03-07 | 2016-09-29 | Intonation Research Laboratories | Inhibitors of histone lysine specific demethylase (LSD1) and histone deacetylases (HDACs) |
| WO2016107603A1 (zh) | 2015-01-01 | 2016-07-07 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| MX375707B (es) | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| WO2017029601A1 (en) | 2015-08-17 | 2017-02-23 | Lupin Limited | Heteroaryl derivatives as parp inhibitors |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| AU2019382044B2 (en) | 2018-11-14 | 2025-07-17 | Smilebiotek Zhuhai Limited | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
| AU2020318599B2 (en) | 2019-07-19 | 2023-09-07 | Astrazeneca Ab | PARP1 inhibitors |
| AU2020376697B2 (en) | 2019-10-30 | 2024-03-14 | Digmbio. Inc. | Isoquinolinone derivative, preparation method therefor, and pharmaceutical composition, comprising same as active ingredient, for prevention or treatment of poly(ADP-ribose)polymerase-1 (PARP-1)-associated disease |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| TW202309025A (zh) | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| MX2023012361A (es) | 2021-04-22 | 2023-10-31 | Wigen Biomedicine Tech Shanghai Co Ltd | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. |
| CN116867784A (zh) | 2021-04-23 | 2023-10-10 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
| WO2022222966A1 (zh) | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| CN116601148A (zh) | 2021-04-23 | 2023-08-15 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| WO2022222995A1 (zh) | 2021-04-23 | 2022-10-27 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| WO2022228387A1 (en) | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
| CA3219858A1 (en) | 2021-05-24 | 2022-12-01 | Xin Li | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
| CN115403595A (zh) | 2021-05-27 | 2022-11-29 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| KR20240021884A (ko) | 2021-06-16 | 2024-02-19 | 리페어 세라퓨틱스 인크. | 암을 치료하기 위한 parp 억제제와 조합된 atr 억제제의 용도 |
| US20240368169A1 (en) * | 2021-08-27 | 2024-11-07 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| WO2023036285A1 (zh) | 2021-09-09 | 2023-03-16 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046158A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023046149A1 (zh) | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023051812A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| EP4410791A4 (en) | 2021-09-30 | 2025-10-22 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLIC DERIVATIVE PARP INHIBITOR AND ITS USE |
| WO2023051716A1 (zh) | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| CN120058698A (zh) | 2021-10-01 | 2025-05-30 | 新特拉有限公司 | 氮杂环丁烷和吡咯烷parp1抑制剂及其用途 |
| WO2023061406A1 (zh) | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| CN118055933B (zh) | 2021-11-19 | 2025-06-06 | 康百达（四川）生物医药科技有限公司 | 选择性parp1抑制剂及其应用 |
| CN116143776A (zh) | 2021-11-22 | 2023-05-23 | 南京圣和药业股份有限公司 | Parp1抑制剂及其应用 |
| US20250051324A1 (en) | 2021-12-17 | 2025-02-13 | Keythera (Suzhou) Bio-Pharmaceuticals Co., Limited | Parp inhibitor, pharmaceutical composition comprising same, and use thereof |
| WO2023133413A1 (en) | 2022-01-07 | 2023-07-13 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| JP2025503798A (ja) | 2022-01-13 | 2025-02-04 | 優領医薬科技（香港）有限公司 | ピペラジン縮合環系含有誘導体、その薬学的に許容される塩及びその製造方法と使用 |
| WO2023138541A1 (zh) | 2022-01-20 | 2023-07-27 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| IL320829A (en) | 2022-01-21 | 2025-07-01 | Xinthera Inc | PARP1 inhibitors and their uses |
| CN116535401A (zh) | 2022-01-25 | 2023-08-04 | 南京圣和药业股份有限公司 | 新的parp1抑制剂及其应用 |
| WO2023143236A1 (zh) | 2022-01-26 | 2023-08-03 | 中国药科大学 | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 |
| CA3246093A1 (en) | 2022-01-27 | 2023-08-03 | Xinthera Inc | PARP1 INHIBITORS AND THEIR USES |
| WO2023147009A1 (en) | 2022-01-27 | 2023-08-03 | The Johns Hopkins University | Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks |
| CA3249318A1 (en) | 2022-01-28 | 2023-08-03 | Xinthera Inc | PARP1 INHIBITORS AND THEIR USES |
| KR20230116457A (ko) | 2022-01-28 | 2023-08-04 | 경북대학교 산학협력단 | 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물 |
| US20250177359A1 (en) | 2022-01-28 | 2025-06-05 | Oulun Yliopisto | Compounds for use in the treatment of cancer and inflammatory conditions |
| EP4444305A2 (en) | 2022-02-16 | 2024-10-16 | Duke Street Bio Limited | Pharmaceutical compound |
| JP2025508122A (ja) * | 2022-03-11 | 2025-03-21 | インパクト セラピューティクス （シャンハイ）， インコーポレイテッド | Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 |
| PT4355749T (pt) | 2022-04-28 | 2025-08-13 | Xinthera Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| WO2023207284A1 (en) | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| US20250289814A1 (en) | 2022-04-28 | 2025-09-18 | Ningbo Newbay Technology Development Co., Ltd. | Compounds as parp1 inhibitiors |
| US20250295642A1 (en) | 2022-05-07 | 2025-09-25 | Medshine Discovery Inc. | Fluoroquinoxalinone derivative for selectively inhibiting parp1 |
| CA3256658A1 (en) | 2022-05-25 | 2025-04-23 | Xizang Haisco Pharmaceutical Co Ltd | BICYCLE-DERIVED PARP INHIBITOR AND ITS USE |
| US20250346573A1 (en) | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| CN117447449A (zh) | 2022-07-13 | 2024-01-26 | 南京圣和药业股份有限公司 | Parp1抑制剂及其应用 |
| CN115232129B (zh) | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| WO2024041643A1 (zh) | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| WO2024050370A1 (en) | 2022-08-30 | 2024-03-07 | 1Cbio, Inc. | Heterocyclic compounds and methods of use thereof |
| CN119365468A (zh) | 2022-08-31 | 2025-01-24 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
| CN117658983A (zh) | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| CN118139862A (zh) | 2022-09-30 | 2024-06-04 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| WO2024067691A1 (zh) | 2022-09-30 | 2024-04-04 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| US20240174669A1 (en) | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| CN120035592A (zh) | 2022-10-20 | 2025-05-23 | 成都赜灵生物医药科技有限公司 | 并杂环类氘代化合物及其用途 |
| WO2024083201A1 (zh) | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| CN120019054A (zh) | 2022-10-20 | 2025-05-16 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| CN117946074A (zh) | 2022-10-20 | 2024-04-30 | 上海海和药物研究开发股份有限公司 | 具有parp1抑制活性的化合物及其用途 |
| WO2024099364A2 (en) | 2022-11-09 | 2024-05-16 | Laekna Therapeutics Shanghai Co., Ltd. | Fused multicyclic compounds and their use as parp1 inhibitors |
| IL320626A (en) | 2022-11-10 | 2025-07-01 | Haihe Biopharma Co Ltd | Fused tricyclic parp1 inhibitor, method of preparation thereof, and use thereof |
| WO2024109871A1 (zh) | 2022-11-23 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| CN118084916A (zh) | 2022-11-25 | 2024-05-28 | 成都赜灵生物医药科技有限公司 | 三并杂环类化合物及其用途 |
| TW202438067A (zh) | 2023-03-24 | 2024-10-01 | 美商辛瑟拉股份有限公司 | 吖呾ｐａｒｐ１抑制劑之晶形 |
| CN116987066B (zh) | 2023-06-20 | 2025-07-25 | 四川大学 | 一种嘧啶类化合物及其制备方法和应用 |
| CN117017962A (zh) | 2023-08-23 | 2023-11-10 | 复旦大学附属肿瘤医院 | 一种hdaci抑制剂在制备治疗卵巢癌药物中的用途 |
-
2023
- 2023-04-27 PT PT237972971T patent/PT4355749T/pt unknown
- 2023-04-27 US US18/140,370 patent/US11795173B1/en active Active
- 2023-04-27 TW TW112115680A patent/TWI891000B/zh active
- 2023-04-27 CA CA3250945A patent/CA3250945A1/en active Pending
- 2023-04-27 EP EP24217893.7A patent/EP4497438B1/en active Active
- 2023-04-27 FI FIEP23797297.1T patent/FI4355749T3/fi active
- 2023-04-27 EP EP25180004.1A patent/EP4620472A3/en active Pending
- 2023-04-27 PL PL23797297.1T patent/PL4355749T3/pl unknown
- 2023-04-27 IL IL316278A patent/IL316278A/en unknown
- 2023-04-27 LT LTEP24217893.7T patent/LT4497438T/lt unknown
- 2023-04-27 PT PT242178937T patent/PT4497438T/pt unknown
- 2023-04-27 ES ES23797297T patent/ES3038967T3/es active Active
- 2023-04-27 EP EP23797297.1A patent/EP4355749B1/en active Active
- 2023-04-27 WO PCT/US2023/020235 patent/WO2023212219A1/en not_active Ceased
- 2023-04-27 CR CR20240461A patent/CR20240461A/es unknown
- 2023-04-27 FI FIEP24217893.7T patent/FI4497438T3/fi active
- 2023-04-27 LT LTEPPCT/US2023/020235T patent/LT4355749T/lt unknown
- 2023-04-27 CN CN202380036872.0A patent/CN119173516A/zh active Pending
- 2023-04-27 HR HRP20250969TT patent/HRP20250969T1/hr unknown
- 2023-04-27 SI SI202330037T patent/SI4355749T1/sl unknown
- 2023-04-27 DK DK24217893.7T patent/DK4497438T3/da active
- 2023-04-27 HR HRP20251173TT patent/HRP20251173T1/hr unknown
- 2023-04-27 DK DK23797297.1T patent/DK4355749T3/da active
- 2023-04-27 HU HUE23797297A patent/HUE072274T2/hu unknown
- 2023-04-27 AU AU2023259236A patent/AU2023259236B2/en active Active
- 2023-04-27 JP JP2024563302A patent/JP7728989B2/ja active Active
- 2023-09-20 US US18/471,250 patent/US12006322B2/en active Active
-
2024
- 2024-05-02 US US18/653,538 patent/US12421241B2/en active Active
- 2024-10-25 CO CONC2024/0014603A patent/CO2024014603A2/es unknown
- 2024-10-25 MX MX2025008920A patent/MX2025008920A/es unknown
- 2024-10-25 CL CL2024003262A patent/CL2024003262A1/es unknown
- 2024-10-25 DO DO2024000218A patent/DOP2024000218A/es unknown
- 2024-10-25 MX MX2024013195A patent/MX2024013195A/es unknown
-
2025
- 2025-04-08 AU AU2025202495A patent/AU2025202495A1/en active Pending
- 2025-08-13 JP JP2025134784A patent/JP2025161856A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4497438T3 (fi) | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja | |
| ZA202209563B (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| IL314009B1 (en) | Parp1 inhibitors and uses thereof | |
| PH12022553378A1 (en) | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| IL311376B2 (en) | Azetidine and pyrrolidine parp1 inhibitors and uses thereof | |
| FI3986897T3 (fi) | Egfr-estäjä syövän hoitoon | |
| EA202092168A1 (ru) | Применение фавипиравира в лечении коронавирусной инфекции | |
| IS7892A (is) | Tetrahýdró-4H-pýridó[1,2-A]pýrimidín og tengd efnasambönd sem nýtast sem HIV integrasa hindrar | |
| MX2022015886A (es) | Derivados de amidopirimidona. | |
| SE0400284D0 (sv) | Novel compounds | |
| FI3846810T3 (fi) | Lasmiditaanin pitkäkestoinen yöaikainen annostus migreenin ennaltaehkäisyyn | |
| DE602004026903D1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| SA523442503B1 (ar) | مشتقات سبيروبيبريدينيل مستبدل بأريل غير متجانس واستخدامات صيدلانية لها | |
| CA2469592A1 (en) | Hiv integrase inhibitors | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| MX2022012881A (es) | Inhibidores de replicacion del virus de inmunodeficiencia humana. | |
| SA520420037B1 (ar) | مركب حلقي من ميثيل لاكتام واستخدامه صيدلانيًا | |
| MX2009007040A (es) | Derivados de mononitrato de isosorbida para el tratamiento de hipertension ocular. | |
| CA3262389A1 (en) | HETEROAROMATIC CYCLIC COMPOUND CONTAINING SULFUR, PHARMACEUTICAL COMPOSITION THEREIN AND ITS USE | |
| CL2024001073A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos |